Refametinib (BAY86-9766)
14747
Phase 1 small_molecule completed
Quick answer
Refametinib (BAY86-9766) for Neoplasms is a Phase 1 program (small_molecule) at Bayer HealthCare AG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Bayer HealthCare AG
- Indication
- Neoplasms
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed